Meeting
2019 ASCO Annual Meeting
Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
Authors
Rahul Raj Aggarwal
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Rahul Raj Aggarwal , Scott Thomas , Nela Pawlowska , Jennifer A. Grabowsky , Susan Calabrese , Phu Lam , Kathleen Comerford , Daphne Bautista , Pamela N. Munster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Cancer Angiogenesis and Metastases
Clinical Trial Registration Number
NCT01543763
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3022)
DOI
10.1200/JCO.2019.37.15_suppl.3022
Abstract #
3022
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies.
First Author: Erica S Tsang
Poster
2013 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.
First Author: Thach-Giao Truong
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani